Martin H. Cohen
Division of Biological Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research
US Food and Drug Administration
USA
Name/email consistency: high
- FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Cohen, M.H., Gootenberg, J., Keegan, P., Pazdur, R. Oncologist (2007)
- U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Cohen, M.H., Johnson, J.R., Pazdur, R. Clin. Cancer Res. (2005)
- FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Cohen, M.H., Johnson, J.R., Wang, Y.C., Sridhara, R., Pazdur, R. Oncologist (2005)
- FDA drug approval summary: erlotinib (Tarceva) tablets. Cohen, M.H., Johnson, J.R., Chen, Y.F., Sridhara, R., Pazdur, R. Oncologist (2005)
- Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Cohen, M.H., Johnson, J.R., Pazdur, R. Clin. Cancer Res. (2005)
- United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Cohen, M.H., Williams, G.A., Sridhara, R., Chen, G., McGuinn, W.D., Morse, D., Abraham, S., Rahman, A., Liang, C., Lostritto, R., Baird, A., Pazdur, R. Clin. Cancer Res. (2004)
- FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Cohen, M.H., Williams, G.A., Sridhara, R., Chen, G., Pazdur, R. Oncologist (2003)